Kena A. Swanson publications per year

The chart shows the history of publications by Kena A. Swanson between 1984 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Kena A. Swanson published across 42 years, from 1984 to 2025, averaging 3.3 papers a year. Output peaked at 28 publications in 2021. 34 of the 138 publications appeared in the last two years.

No. of publications

5 10 15 20 25

1984 2025

138 publications in total across all disciplines

View publications per year as a table

Kena A. Swanson: publications per year, 1984 to 2025
Year	Publications
1984	1
1985	0
1986	0
1987	0
1988	0
1989	0
1990	0
1991	0
1992	0
1993	0
1994	0
1995	0
1996	0
1997	0
1998	0
1999	0
2000	0
2001	0
2002	0
2003	1
2004	2
2005	2
2006	0
2007	1
2008	0
2009	1
2010	0
2011	0
2012	0
2013	0
2014	0
2015	2
2016	0
2017	0
2018	1
2019	2
2020	14
2021	28
2022	24
2023	25
2024	14
2025	20
Total	138

Download as CSV

Kena A. Swanson publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kena A. Swanson sits on this spectrum.

No. of scientists

50 100 150

62–71 publications 807+

This scientist: 134 publications — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table

Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications	Scientists	This scientist
62–71	9
72–81	23
82–91	40
92–101	72
102–111	86
112–121	108
122–131	150
132–141	160	134
142–151	159
152–161	189
162–171	166
172–181	181
182–191	188
192–201	187
202–211	178
212–221	158
222–231	168
232–241	159
242–251	160
252–261	148
262–271	116
272–281	125
282–291	115
292–301	111
302–311	95
312–321	97
322–331	97
332–341	99
342–351	96
352–361	69
362–371	76
372–381	71
382–391	71
392–401	62
402–411	54
412–421	41
422–431	63
432–441	53
442–451	31
452–461	42
462–471	40
472–481	29
482–491	34
492–501	30
502–511	23
512–521	41
522–531	29
532–541	28
542–551	16
552–561	18
562–571	18
572–581	17
582–591	17
592–601	17
602–611	19
612–621	13
622–631	12
632–641	11
642–651	16
652–661	9
662–671	5
672–681	13
682–691	12
692–701	6
702–711	6
712–721	9
722–731	9
732–741	6
742–751	11
752–761	10
762–771	7
772–781	12
782–791	7
792–801	5
802–806	1
807+	100

Download as CSV

Kena A. Swanson D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kena A. Swanson sits on this spectrum.

No. of scientists

50 100 150 200

40–41 D-Index 157+

This scientist: 49 D-Index — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table

Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index	Scientists	This scientist
40–41	28
42–43	91
44–45	157
46–47	192
48–49	175	49
50–51	188
52–53	177
54–55	155
56–57	194
58–59	201
60–61	197
62–63	201
64–65	173
66–67	167
68–69	172
70–71	199
72–73	184
74–75	133
76–77	163
78–79	127
80–81	121
82–83	125
84–85	121
86–87	102
88–89	96
90–91	75
92–93	72
94–95	74
96–97	66
98–99	68
100–101	49
102–103	60
104–105	54
106–107	36
108–109	23
110–111	52
112–113	41
114–115	34
116–117	25
118–119	28
120–121	11
122–123	20
124–125	27
126–127	19
128–129	20
130–131	16
132–133	17
134–135	14
136–137	15
138–139	9
140–141	11
142–143	9
144–145	9
146–147	7
148–149	7
150–151	7
152–153	5
154–155	8
156	6
157+	96

Download as CSV

Best Publications

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

14076
Citations
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

2629
Citations
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

2204
Citations
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

1672
Citations
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

Unknown

992
Citations
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

847
Citations
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

Annette B. Vogel;Isis Kanevsky;Ye Che;Kena A. Swanson

686
Citations
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

Unknown

678
Citations
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

Unknown

676
Citations
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

599
Citations
Neutralizing Activity of BNT162b2-Elicited Serum.

Yang Liu;Jianying Liu;Hongjie Xia;Xianwen Zhang

582
Citations
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.

Xuping Xie;Yang Liu;Jianying Liu;Xianwen Zhang

580
Citations
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.

Alexander Muik;Ann-Kathrin Wallisch;Bianca Sänger;Kena A. Swanson

527
Citations
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

Ann R Falsey;Robert W Frenck;Edward E Walsh;Nicholas Kitchin

373
Citations
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.

Jianying Liu;Yang Liu;Hongjie Xia;Jing Zou

342
Citations
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Unknown

244
Citations
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Unknown

182
Citations
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

Unknown

178
Citations
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

Unknown

175
Citations
RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study

Edward E. Walsh;Robert Frenck;Ann R. Falsey;Nicholas Kitchin

170
Citations